ArticleBMC oral health2025
Medication-related osteonecrosis of the jaw: who knows more? A cross-sectional study of general dental practitioners and oral maxillofacial surgery assistants.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesAnti-resorptive and anti-angiogenic drugs, commonly prescribed for osteoporosis, bone metastases, and metabolic bone diseases, increase the risk of medication-related osteonecrosis of the jaw (MRONJ) following dentoalveolar surgery. This study aimed to assess the knowledge of general dental practitioners and oral and maxillofacial surgery (OMFS) assistants regarding these drugs, MRONJ, and related treatment approaches. Methods: A questionnaire addressing demographics, familiarity with these medications, understanding of MRONJ, and treatment strategies was electronically distributed. Participants were classified into general dental practitioners and OMFS assistants. Data were analyzed using chi-square tests with a significance threshold of 0.05. Results: Awareness of MRONJ risk was significantly higher among OMFS assistants (98.3%) than general dental practitioners (75.8%). OMFS assistants were more likely to consult prescribing physicians before tooth extraction (99.2% vs. 91.7%) and correctly identify the mandible as the most commonly affected jaw (97.3% vs. 65.8%). Knowledge of drug discontinuation before dentoalveolar surgery in patients using denosumab was higher in OMFS assistants (66.4% vs. 31.7%). OMFS assistants also demonstrated greater familiarity with the conditions treated by these drugs, including osteoporosis (98.3% vs. 83.3%), breast cancer (91.4% vs. 54.1%), and multiple myeloma (87.1% vs. 40.8%). Conclusion: Dentists undergoing specialty or doctoral training demonstrated greater knowledge and awareness of MRONJ and related treatment approaches compared to general dental practitioners, highlighting the need for targeted educational programs to improve clinical practice and patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.